Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1-infected children and adolescents in Rwanda

Pediatric Infectious Disease Journal

Volumn 33, Issue 1, 2014, Pages 63-69

  Mutwa, Philippe R ^a,b,c   Boer, Kimberly R ^b,c,d   Rusine, John ^b,c,e   Muganga, Narcisse ^a   Tuyishimire, Diane ^b,c,f   Schuurman, Rob ^g   Reiss, Peter ^b,c   Lange, Joep M A ^b,c   Geelen, Sibyl P M ^b,c,h  

^a Centre Hospitalier Universitaire de Kigali   (Rwanda)

^b AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ROYAL TROPICAL INSTITUTE   (Netherlands)

^e National Reference Laboratory   (Rwanda)

^f Treatment and Research on HIV/AIDS Centre (TRAC plus)   (Rwanda)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Children; Combination Antiretroviral Therapy; HIV Drug Resistance; Outcomes; Rwanda

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BODY WEIGHT; CD4+ T LYMPHOCYTE; CHILD; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; RWANDA; SCHOOL CHILD; STUNTING; TREATMENT DURATION; TREATMENT OUTCOME; UNDERWEIGHT; VIROLOGY; VIRUS LOAD; VIRUS MUTATION;

ANTI-RETROVIRAL AGENTS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; PREVALENCE; RWANDA; TREATMENT OUTCOME;

EID: 84891539235     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829e6b9f     Document Type: Article

References (49)

1. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, et al. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007;298:1888-1899
2. Brady MT, Oleske JM, Williams PL, et al.; Pediatric AIDS Clinical Trials Group219/219C Team. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010;53:86-94
3. Gortmaker SL, Hughes M, Cervia J, et al.; Pediatric AIDS Clinical Trials Group Protocol 219 Team. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528
4. Judd A, Doerholt K, Tookey PA, et al.; Collaborative HIV Paediatric Study (CHIPS); National Study of HIV in Pregnancy and Childhood (NSHPC). Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: Planning for teenage and adult care. Clin Infect Dis. 2007;45:918-924
5. Sánchez JM, Ramos Amador JT, Fernández de Miguel S, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:863-867
6. Mutagoma M, Hinda R, Nyankesha E, et al. HIV and AIDS in Rwanda Epidemiologic Update. 2010. Available at: Http://rbc.gov.rw/IMG/pdf/2010- epidemiologic-update.pdf. Accessed January 13, 2012
7. Rwanda Ministry of Health. Ministry of Health Annual Report. 2010-2011. Available at: Http://moh.gov.rw/english/?page-id=2212. Accessed February 23, 2012
8. Malawi Paediatric Antiretroviral Treatment Group. Antiretroviral therapy for children in the routine setting in Malawi. Trans R Soc Trop Med Hyg. 2007;101:511-516
9. Davies MA, Keiser O, Technau K, et al.; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration. Outcomes of the South African National Antiretroviral Treatment Programme for children: The IeDEA Southern Africa collaboration. S Afr Med J. 2009;99:730-737
10. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire. AIDS. 2004;18:1905-1913
11. Rouet F, Fassinou P, Inwoley A, et al.; ANRS 1244/1278 Programme Enfants Yopougon. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS. 2006;20:2315-2319
12. S ophan S, Meng CY, Pean P, et al. Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART). Southeast Asian J Trop Med Public Health. 2010;41:126-137
13. Abrams EJ, Weedon J, Steketee RW, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIVinfected infants. New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis. 1998;178:101-108
14. Kamya MR, Mayanja-Kizza H, Kambugu A, et al.; Academic Alliance for AIDS Care and Prevention in Africa. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:187-193
15. Menson EN, Walker AS, Sharland M, et al.; Collaborative HIV Paediatric Study Steering Committee. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: Cohort study. BMJ. 2006;332:1183-1187
16. Phelps BR, Rakhmanina N. Antiretroviral drugs in pediatric HIV-infected patients: Pharmacokinetic and practical challenges. Paediatr Drugs. 2011;13:175-192
17. Walker AS, Doerholt K, Sharland M, et al.; Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Response to highly active antiretroviral therapy varies with age: The UK and Ireland Collaborative HIV Paediatric Study. AIDS. 2004;18:1915-1924
18. Hunt GM, Coovadia A, Abrams EJ, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011;25:1461-1469
19. McConnell MS, Stringer JS, Kourtis AP, et al. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: Does development of resistance matter? Am J Obstet Gynecol. 2007;197(suppl 3):S56-S63
20. Rwanda Ministry of Health. Guidelines for the Provision of Comprehensive Care to Persons Infected by HIV in Rwanda. 2009
21. World Health Organization. Antiretroviral Therapy of HIV Infection in Infants and Children: Towards Universal Access. 2010. Available at: Http:// whqlibdoc.who.int/publications/2010/9789241599801-eng.pdf. Accessed January 28, 2012
22. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393-1401
23. Barth RE, Tempelman HA, Moraba R, et al. Long-term outcome of an HIVtreatment programme in Rural Africa: Viral suppression despite early mortality. AIDS Res Treat. 2011;2011:434375
24. Van GJ, De NL, Uwera J, et al. Success with antiretroviral treatment for children in Kigali, Rwanda: Experience with health center/nurse-based care. BMC Pediatr. 2008;8:39
25. Kiboneka A, Wangisi J, Nabiryo C, et al. Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. AIDS. 2008;22:2493-2499
26. Sutcliffe CG, Van Dijk JH, Bolton C, et al. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis. 2008;8:477-489
27. Sutcliffe CG, Van Dijk JH, Munsanje B, et al. Weight and height z-scores improve after initiating ART among HIV-infected children in rural Zambia: A cohort study. BMC Infect Dis. 2011;11:54
28. Musoke PM, Mudiope P, Barlow-Mosha LN, et al. Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: A prospective cohort study. BMC Pediatr. 2010;10:56
29. Puthanakit T, Kerr S, Ananworanich J, et al. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J. 2009;28:488-492
30. Hazra R, Mackall C. Thymic function in HIV infection. Curr HIV/AIDS Rep. 2005;2:24-28
31. Ye P, Kirschner DE, Kourtis AP. The thymus during HIV disease: Role in pathogenesis and in immune recovery. Curr HIV Res. 2004;2:177-183
32. Rwanda Ministy of Health. Guidelines for the Provision of Comprehensive Care to Persons Infected by HIV in Rwanda. 2011
33. Davies MA, Moultrie H, Eley B, et al.; International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration. Virologic failure and second-line antiretroviral therapy in children in South Africa-the IeDEA Southern Africa collaboration. J Acquir Immune Defic Syndr. 2011;56:270-278
34. Bacha T, Tilahun B, Worku A. Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first line anti-retroviral therapy. BMC Infect Dis. 2012;12:197
35. E mmett SD, Cunningham CK, Mmbaga BT, et al. Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: A cross-sectional study. J Acquir Immune Defic Syndr. 2010;54:368-375
36. Bratholm C, Johannessen A, Naman E, et al. Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital. J Antimicrob Chemother. 2010;65:1996-2000
37. Chaix ML, Rouet F, Kouakoussui KA, et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire. Pediatr Infect Dis J. 2005;24:1072-1076
38. Germanaud D, Derache A, Traore M, et al. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. J Antimicrob Chemother. 2010;65:118-124
39. Lwembe R, Ochieng W, Panikulam A, et al. Anti-retroviral drug resistanceassociated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. J Med Virol. 2007;79:865-872
40. D'Aquila RT, Schapiro JM, Brun-Vézinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med. 2003;11:92-96
41. Hirsch MS, Günthard HF, Schapiro JM, et al.; International AIDS Society-USA. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top HIV Med. 2008;16:266-285
42. Luber AD. Genetic barriers to resistance and impact on clinical response. MedGenMed. 2005;7:69
43. Towler WI, Barlow-Mosha L, Church JD, et al. Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. AIDS Res Hum Retroviruses. 2010;26:563-568
44. Ruel TD, Kamya MR, Li P, et al. Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children. J Acquir Immune Defic Syndr. 2011;56:44-50
45. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-1183
46. Ford N, Darder M, Spelman T, et al. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: Five-year follow up of an observational cohort. PLoS One. 2010;5:e10460
47. Kikuchi K, Poudel KC, Muganda J, et al. High risk of ART non-adherence and delay of ART initiation among HIV positive double orphans in Kigali, Rwanda. PLoS One. 2012;7:e41998
48. Mutwa PR, Van Nuil JI, Asiimwe-Kateera B, et al. Living situation affects adherence to combination antiretroviral therapy in HIV-infected adolescents in Rwanda: A qualitative study. PLoS One. 2013;8:e60073
49. S canlon ML, Vreeman RC. Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings. HIV AIDS (Auckl). 2013;5:1-17